

IN THE CLAIMS

Please amend the claims as shown on the marked-up copy following this amendment to read as follows.

3. (Amended) The agent of claim 1, wherein the macrolide compound is FK506.
4. (Amended) The agent of claim 1, which is in the form of a preparation for local administration to the eye.
5. (Amended) The agent of claim 1, which aims at improving tear film breakup time.

REMARKS

Claims 1-7 are active in the present application. Claims 2-5 have been amended to remove multiple dependencies. The specification has been amended to correct a typographical or clerical error. No new matter is believed to have been added. An action on the merits and allowance of claims is solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.



Norman F. Oblon  
Attorney of Record  
Registration No. 24,618

Daniel J. Pereira, Ph.D.  
Registration No. 45,518



**22850**

(703) 413-3000  
NFO/DJP/smi  
I:\atty\SUKOS\215246US-pr.wpd